Download PDF
Clin Colon Rectal Surg 2020; 33(05): 247-252
DOI: 10.1055/s-0040-1713741
Review Article

Perforated Colorectal Cancer

Alexios Tzivanakis
1   Peritoneal Malignancy Institute, Basingstoke, Hampshire, United Kingdom
,
Brendan J. Moran
1   Peritoneal Malignancy Institute, Basingstoke, Hampshire, United Kingdom
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

The majority of patients with colorectal tumors will present via the elective route. However, one-fifth of patients will present as an emergency. The most common cause of emergency presentation of colorectal cancer is obstruction followed by perforation, and in many cases, patients will present with both. We discuss the management of the patient presenting with a perforated colorectal tumor covering the acute presentation and also how to deal with consequences of a perforated tumor, namely, the management of colorectal peritoneal metastasis (CPM). CPM used to be considered a terminal condition; however, a strategy of early detection of CPM, careful patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, leads to much improved outcomes and even cure, in some patient compared with systemic chemotherapy alone.

Keywords

perforated colorectal cancer - peritoneal carcinomatosis - CRS and HIPEC


Publication History

Article published online:
20 July 2020

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Annual Report of the National Bowel Cancer Audit. Accessed May 6, 2018 at: https://www.nboca.org.uk
  • 2 Survival of colorectal Cancer per stage, Cancer Research UK. Accessed May 6, 2018at: http://www.cancerresearchuk.org
  • 3 Sjödahl R, Franzén T, Nyström PO. Primary versus staged resection for acute obstructing colorectal carcinoma. Br J Surg 1992; 79 (07) 685-688
    CrossrefPubMedGoogle Scholar
  • 4 Runkel NS, Schlag P, Schwarz V, Herfarth C. Outcome after emergency surgery for cancer of the large intestine. Br J Surg 1991; 78 (02) 183-188
    CrossrefPubMedGoogle Scholar
  • 5 Hogan J, Samaha G, Burke J. , et al. Emergency presenting colon cancer is an independent predictor of adverse disease-free survival. Int Surg 2015; 100 (01) 77-86
    CrossrefPubMedGoogle Scholar
  • 6 Baer C, Menon R, Bastawrous S, Bastawrous A. Emergency presentations of colorectal cancer. Surg Clin North Am 2017; 97 (03) 529-545
    CrossrefPubMedGoogle Scholar
  • 7 Yamamoto T, Kita R, Masui H. , et al. Prediction of mortality in patients with colorectal perforation based on routinely available parameters: a retrospective study. World J Emerg Surg 2015; 10 (01) 24
    CrossrefPubMedGoogle Scholar
  • 8 National Emergency Laparotomy Audit, United Kingdom. Accessed May 14, 2018 at: http://nela.org.uk/reports
  • 9 Dellinger RP, Levy MM, Carlet JM. , et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34 (01) 17-60
    CrossrefPubMedGoogle Scholar
  • 10 Daniels R, Nutbeam T, McNamara G, Galvin C. The sepsis six and the severe sepsis resuscitation bundle: a prospective observational cohort study. Emerg Med J 2011; 28 (06) 507-512
    CrossrefPubMedGoogle Scholar
  • 11 Constantinides VA, Tekkis PP, Athanasiou T. , et al. Primary resection with anastomosis vs. Hartmann's procedure in nonelective surgery for acute colonic diverticulitis: a systematic review. Dis Colon Rectum 2006; 49 (07) 966-981
    CrossrefPubMedGoogle Scholar
  • 12 Accessed May 10, 2018 at: https://www.nice.org.uk/Guidance/cg131
  • 13 Cunningham D, Atkin W, Lenz HJ. , et al. Colorectal cancer. Lancet 2010; 375 (9719): 1030-1047
    CrossrefPubMedGoogle Scholar
  • 14 Umpleby HC, Fermor B, Symes MO, Williamson RC. Viability of exfoliated colorectal carcinoma cells. Br J Surg 1984; 71 (09) 659-663
    CrossrefPubMedGoogle Scholar
  • 15 Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89 (12) 1545-1550
    CrossrefPubMedGoogle Scholar
  • 16 Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63 (02) 364-367
    CrossrefPubMedGoogle Scholar
  • 17 Sadeghi B, Arvieux C, Glehen O. , et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer: Interdisciplinary International. J Am Cancer Soc 2000; 88 (02) 358-363
    PubMedGoogle Scholar
  • 18 Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994; 219 (02) 109-111
    CrossrefPubMedGoogle Scholar
  • 19 Moran BJ, Cecil TD. Treatment of surgically resectable colorectal peritoneal metastases. Br J Surg 2014; 101 (02) 5-7
    CrossrefPubMedGoogle Scholar
  • 20 Hall B, Padussis J, Foster JM. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastasis. Surg Clin North Am 2017; 97 (03) 671-682
    CrossrefPubMedGoogle Scholar
  • 21 Franko J, Shi Q, Goldman CD. , et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30 (03) 263-267
    CrossrefPubMedGoogle Scholar
  • 22 Klaver YL, Simkens LH, Lemmens VE. , et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 2012; 38 (07) 617-623
    CrossrefPubMedGoogle Scholar
  • 23 Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg 1989; 32 (03) 164-170
    PubMedGoogle Scholar
  • 24 Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 2015; 17 (09) 772-778
    CrossrefPubMedGoogle Scholar
  • 25 Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999; 23 (01) 23-29
    CrossrefPubMedGoogle Scholar
  • 26 Prada-Villaverde A, Esquivel J, Lowy AM. , et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 2014; 110 (07) 779-785
    CrossrefPubMedGoogle Scholar
  • 27 Verwaal VJ, van Ruth S, de Bree E. , et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21 (20) 3737-3743
    CrossrefPubMedGoogle Scholar
  • 28 Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15 (09) 2426-2432
    CrossrefPubMedGoogle Scholar
  • 29 Elias D, Gilly F, Boutitie F. , et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28 (01) 63-68
    CrossrefPubMedGoogle Scholar
  • 30 Elias D, Faron M, Iuga BS. , et al. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg 2015; 261 (01) 157-163
    CrossrefPubMedGoogle Scholar
  • 31 Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 2011; 18 (02) e84-e96
    CrossrefPubMedGoogle Scholar
  • 32 Elias D, Honoré C, Dumont F. , et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011; 254 (02) 289-293
    CrossrefPubMedGoogle Scholar
  • 33 Honoré C, Goéré D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 2013; 20 (01) 183-192
    CrossrefPubMedGoogle Scholar
  • 34 Moran BJ, Tzivanakis A. The concept of “Obstruction-Free Survival” as an outcome measure in advanced colorectal cancer management. Pleura and peritoneum. 2018 3. (01)
    Google Scholar